ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,960.61
-0.66%
S&P 500
5,702.55
-0.19%
Dow Jones
42,063.36
0.09%
US Dollar vs Yen
143.825
0.00%
Brent Oil
74.135
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) ニュース

NBIX

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NBIX
日付受信時刻ニュースソース見出しコード企業名
2024/09/2005 : 01PR Newswire (US)Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual SummitNASDAQ:NBIXNeurocrine Biosciences Inc
2024/09/1805 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/09/1405 : 23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/09/1305 : 05PR Newswire (US)Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
2024/09/1105 : 01PR Newswire (US)Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/2905 : 05PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in SeptemberNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/2820 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/2820 : 00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with SchizophreniaNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/1706 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/1606 : 21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/1606 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/1606 : 06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0906 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0805 : 01PR Newswire (US)Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0606 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0606 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0123 : 51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
2024/08/0120 : 00PR Newswire (US)Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales GuidanceNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1906 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1906 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1905 : 41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1821 : 30PR Newswire (US)Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty SwallowingNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
2024/07/1705 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

最近閲覧した銘柄

NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
COIN
SOLUSD
Solana
COIN
ADAUSD
Cardano
AMEX
XLF
Financial Select Sector
USOTC
BASFY
BASF (QX)
NYSE
XOM
Exxon Mobil
FX
USDJPY
US Dollar vs Yen
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
NYSE
AXP
American Express
COIN
ETHUSD
Ethereum
SPI
SP500
S&P 500
PM
XAUUSD
Gold vs US Dollar
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有